Evidence map›Paper›PMID 40524708›Full record

ArticleJournal of pathology informatics2025

Deep learning predicts the effect of neoadjuvant chemotherapy for patients with triple negative breast cancer.

B Sturm, P Lock, D Kumar, W A M Blokx, J A W M van der Laak

Erratum issuedAbstract read
In one paragraph

Article in Journal of pathology informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

B SturmDepartment of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
P LockKentalis, Goes, the Netherlands.
D KumarAiforia Technologies Plc, Helsinki, Finland.
W A M BlokxDepartment of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
J A W M van der LaakDepartment of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple negative breast cancer (TNBC) is an aggressive subcategory of breast cancer with poor prognosis and high risk of recurrence after treatment. In a subset of cases systemic chemotherapy is offered before surgery, so called neoadjuvant chemotherapy (NAC), to downstage the disease resulting in 40-50% of cases to a pathological complete response. Meanwhile, patients receiving NAC suffer from toxic side effects and in a proportion of patients a significant amount of residual tumor remains. This study aims to predict the outcome of NAC with deep learning technology based on the microscopic morphological characteristics in whole slide images of hematoxylin and eosin (H&E) slides from the pre-operative tumor biopsy before chemotherapy. Methods: A convolutional neural network was trained on 221 H&E-stained biopsies of carcinoma of no special type from 205 patients scanned at 40×. Cases were divided in three cohorts, with a good, moderate, or bad response to NAC based on the EUSOMA scoring according to the pathology report of the subsequent tumor surgery specimen. We defined good, moderate, and bad response as residual tumor <10%, 10-50%, and >50%, respectively. Manual segmentation of the tumor area was performed comprising invasive carcinoma with a small rim of surrounding benign tissue. The model was tested on 52 new biopsies of 50 patients. Because of the relative low number of moderate and bad responder cases, and to achieve a better discrimination for potential visual biomarkers, the moderate and bad response cohorts were merged. Results: The predictive performance of the model was calculated by means of the area under the receiver operator curve (AUC ROC). 95% Confidence intervals (CIs) were calculated for better understanding of the range of values. In the test set, the AUC ROC performance score was 0.696 with a CI of 0.532-0.861. Conclusion: This proof-of-concept study shows that H&E pre-operative biopsies from TNBC, by means of deep learning technology, contain valuable information having predictive value for the outcome of NAC resulting in an AUC value of 0.696 outperforming a predictive AUC value of 0.63 based on structured clinical data of histological tumor grade, TILs, and ki-67 known from the literature.

Indexed as

Artificial intelligenceBreast cancerChemotherapyDeep learningPredictionWSI

Identifiers

PMID40524708
PMCPMC12169771

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.